Mutations in SCN5A, encoding the cardiac sodium (Na) channel, are linked to a form of the congenital long-QT syndrome (LQT3) that provokes lethal ventricular arrhythmias. These autosomal dominant mutations disrupt Na channel function, inhibiting channel inactivation, thereby causing a sustained ionic current that delays cardiac repolarization. Sodium channel-blocking antiarrhythmics, such as lidocaine, potently inhibit this pathologic Na current (I Na ) and are being evaluated in patients with LQT3. The mechanism underlying this effect is unknown, although high-affinity "block" of the open Na channel pore has been proposed. Here we report that a recently identified LQT3 mutation (R1623Q) imparts unusual lidocaine sensitivity to the Na channel that is attributable to its altered functional behavior. Studies of lidocaine on individual R1623Q single-channel openings indicate that the open-time distribution is not changed, indicating the drug does not block the open pore as proposed previously. Rather, the mutant channels have a propensity to inactivate without ever opening ("closed-state inactivation"), and lidocaine augments this gating behavior. An allosteric gating model incorporating closed-state inactivation recapitulates the effects of lidocaine on pathologic I Na . These findings explain the unusual drug sensitivity of R1623Q and provide a general and unanticipated mechanism for understanding how Na channel-blocking agents may suppress the pathologic, sustained Na current induced by LQT3 mutations. Japanese girl who had the long-QT syndrome and who was effectively treated with mexiletine, a lidocaine analogue (21). Heterologous expression of human heart Na channels (hH1) with R1623Q revealed destabilized inactivation from the open state (22, 23) consistent with the important role of the domain IV-S4 charge sensor in inactivation gating (24, 25) . In addition, it appeared that this disrupted inactivation phenotype, in analogy to the other LQT3 disorders, was at least partly corrected by lidocaine (22).
Introduction
Although our understanding of the drug targets and therapeutic options for cardiac arrhythmias has expanded over the last decade, insight into the functional mechanism of antiarrhythmic drug action is incomplete, and the pharmacologic management of arrhythmias remains plagued by poor efficacy and unacceptable toxicity. Sodium (Na) channel "blockers" are widely used to treat all forms of life-threatening cardiac arrhythmias but may be particularly useful in managing patients with autosomal dominant forms of the long-QT syndrome that involve mutations in the cardiac Na channel gene SCN5A (LQT3) (1) . An improved understanding of the molecular pharmacology of Na channel blockers in this relatively rare inherited disorder may advance the clinical management of these patients while improving our understanding of drug action in more common, acquired forms of sudden cardiac death.
Cardiac Na channels initiate excitation in the atria and ventricles, but normally open only briefly, fully inactivating within a few milliseconds. The LQT3 mutations involve amino acid residues that reside in domains critical to the inactivating function of Na channels (in the III-IV interdomain linker [2, 3] and vicinal residues [4] [5] [6] [7] [8] ). Hence, these mutations destabilize inactivation and sustain the Na current (I Na ) during the action potential plateau (9) (10) (11) . This pathologic, sustained I Na delays cellular repolarization, prolonging the electrocardiographic QT interval and predisposing patients to polymorphic ventricular tachycardia. Lidocaine binds to amino acids positioned on the intracellular side of the aqueous, ion-conducting pore (12) (13) (14) , near (and perhaps overlapping) the inactivation gating domains (15) . It is apparent that lidocaine and its analogues reduce the pathologic current through Na channels with SCN5A mutations (10, 16) , and this may underlie the beneficial clinical effect of these agents in patients with LQT3 disorders (17) . However, the molecular basis for this pharmacologic effect remains unclear.
Suppression of the pathologic Na current might involve a high-affinity interaction between lidocaine and the open conducting state of the Na channel (18) whereby the drug essentially "plugs" the open pore. Alternatively, the drugs might somehow enhance or "repair" the disordered inactivation gating function (19, 20) . Recently, a sporadic missense mutation in the voltage-sensing region of the cardiac Na channel (the S4 segment of domain IV; R1623Q) was reported in a Japanese girl who had the long-QT syndrome and who was effectively treated with mexiletine, a lidocaine analogue (21) . Heterologous expression of human heart Na channels (hH1) with R1623Q revealed destabilized inactivation from the open state (22, 23) consistent with the important role of the domain IV-S4 charge sensor in inactivation gating (24, 25) . In addition, it appeared that this disrupted inactivation phenotype, in analogy to the other LQT3 disorders, was at least partly corrected by lidocaine (22) .
Here we report that the R1623Q Na channel is unusually sensitive to lidocaine. Surprisingly, we find that lidocaine neither plugs the open channel, nor repairs the inactivation of open channels as proposed previously (22) . Rather, our findings reveal an unanticipated mechanism for lidocaine action. We find that lidocaine augments an intrinsic inactivation gating process that is amplified in R1623Q, known as closed-state inactivation, and thereby prevents channel opening altogether. Our results reveal a molecular mechanism for the unusual lidocaine sensitivity of this particular mutant, while implicating closed-state inactivation as an important functional therapeutic target for Na channel-blocking agents in other long QT disorders.
Methods
Site-directed mutagenesis of residue R1623 in the hH1 Na channel α subunit was performed using standard methods (26) and was sequence verified. For expression in Xenopus oocytes, α-subunit cRNAs were coinjected with an equimolar ratio of β 1 subunit cRNA as described previously (22) . For study in mammalian cells, both wildtype and R1623Q full-length α-subunit cDNAs were subcloned from the host vector pSP64T into the HindI-II-XbaI site of vector pGFPIRS for bicistronic expression of the channel and GFP reporter proteins (27) . Stable cell lines were generated by first linearizing the plasmids at the AseI site. Linearized DNA was transfected into HEK293 cells (CRL-1573, American Type Culture Collection, Manassas, Virginia, USA) using Lipofectamine (Life Technologies, Rockville, Maryland, USA) as directed by the manufacturer. Forty-eight hours after transfection, cells were cultured in DMEM (CellGro; Mediatech, Washington, DC, USA) supplemented with 10% FBS, 2 mM Glutamax, 1 × penicillin-streptomycin, 15 mM HEPES, pH 7.4, and 500 µg/mL geneticin sulfate (G 418; Life Technologies) at 37°C in a 5% CO 2 -humidified incubator. After 1-2 weeks of selection, single colonies were isolated based on their level of fluorescence and examined by patch-clamp analysis. Desirable clones were maintained in selection media for further analysis.
Whole-cell Na currents (I Na ) were recorded from oocytes with a 2-electrode voltage clamp using ND-96 solution containing (in mM): 96 NaCl, 2 KCl, 1 MgCl 2 , 5 HEPES, pH 7.6. I Na was recorded from HEK cells expressing either wild-type or R1623Q Na channels at room temperature using the whole-cell configuration of the patch clamp (28) 7.4 . Pipettes were filled with a recording solution containing (in mM): 140 NaCl, 10 HEPES, pH 7.4. Singlechannel currents were filtered at 2 kHz, sampled every 50 microseconds, and were idealized using a half-height criterion with 3-point detection. Lidocaine HCl (1.5% preservative-free; Abbott Laboratories, Abbott Park, Illinois, USA) was added to the patch pipette (single channels) or the bath solution (whole-cell currents) in appropriate amounts to give the concentrations indicated in each figure legend. In all cases, data were recorded after a 5-minute equilibration period.
Pooled data are expressed as means ± SD, and statistical comparisons were made using 1-way ANOVA. Exponential or Boltzmann functions were fitted to the data using nonlinear least-squares methods (Microcal Origin; Microcal Inc., Northhampton, Massachusetts, lidocaine. τ 50 represents the time (ms) from peak I Na to 50% decay (R1623Q control, n = 17; R1623Q 200 µM lidocaine, n = 14; wildtype control, n = 9; wild-type 200 µM lidocaine, n = 9). For R1623Q, τ 50 was significantly reduced by lidocaine ( A P < 0.01). (c) Summary of paired data comparing the fractional reduction of peak I Na in the presence versus the absence of 200 µM lidocaine for oocytes expressing either R1623Q (left bar, n = 14) or wild-type (right bar, n = 9). Lidocaine suppression of peak I Na was greater for R1623Q ( A P < 0.05).
USA). The sensitivities of Markov gating models to lidocaine block (see Figure 7 ) were examined using numerical integration methods tailored for stiff sets of differential equations (29, 30) and linked to customwritten software as described previously (31) .
Results
Lidocaine effects on whole oocyte R1623Q currents. To examine the general features of R1623Q gating and lidocaine block, we examined whole oocyte I Na (Figure 1 ). Wildtype ( Figure 1a , part i) and R1623Q ( Figure 1a , part ii) I Na is shown before and during exposure to 200 µM lidocaine. As shown previously, a major feature of the drug-free R1623Q phenotype is slowed decay of I Na (22, 23) , a feature that differs from LQT3 mutations in or near the III-IV linker (10, 11, 15) . Figure 1a illustrates that lidocaine has little effect on the rate of wild-type I Na decay, but speeds the decay of R1623Q I Na , partly correcting the abnormal phenotype (22) . The I Na decay rate was quantified using a model-independent index: the time from peak current to 50% decay (τ 50 ). The summary data demonstrate that lidocaine not only speeds the rate of R1623Q I Na decay (Figure 1b, A P < 0.01), but also blocks R1623Q peak I Na more potently than wild-type ( Figure 1c , A P < 0.05). To identify a unifying mechanism for these distinct lidocaine effects, we examined Nachannel gating more precisely using whole-cell and cellattached patch recordings in cultured mammalian cells.
Lidocaine effects on whole-cell R1623Q current in HEK-293 cells. Figure 2a shows wild-type (left) and R1623Q (right) I Na in the absence (top) and presence (bottom) of 200 µM lidocaine. Consistent with the whole-oocyte data, the phenotype of R1623Q in cultured cells included a slowed rate of I Na decay. Furthermore, lidocaine had a small effect on wild-type I Na decay, but markedly speeded the decay of R1623Q I Na . Figure 2b quantifies the effects of lidocaine on I Na decay (τ 50 ) over a range of membrane potentials. Intriguingly, the extent to which lidocaine sped the decay rate was relatively independent of voltage (change in mean τ 50 was 38% at -30 mV vs. 33% at +20 mV), despite a significant voltage dependence in the rate of I Na decay. At a more physiologically relevant lidocaine concentration (20 µM), R1623Q τ 50 at -20 mV was still reduced to 2.7 ± 0.8 milliseconds (n = 7, not shown) compared with control (4.5 ± 0.2 milliseconds; n = 18, P < 0.001).
The surprising lack of voltage-dependence in the blocking effect in Figure 2b led us to speculate that lidocaine influences R1623Q current decay through a mechanism distinct from open-state block. The cardiac Na channel is incompletely available at typical "resting" membrane potentials (-100 mV to -90 mV) owing to a substantial degree of inactivation from closed (preopen) states (32) . We considered whether closed-state inactivation is enhanced by the R1623Q mutation and, if so, whether this altered gating behavior is the basis of the augmented lidocaine sensitivity of the mutant channel. The voltage-dependent availability of wildtype and R1623Q channels was examined over a range of membrane potentials negative to the channel-opening threshold (Figure 3, inset) . Figure 3a shows peak I Na plotted as a function of the conditioning voltage (normalized to the -120 mV measurement). The solid curves represent nonlinear least-squares fits of a Boltzmann function to the data (see Figure 3 legend). R1623Q V 1/2 was shifted leftward relative to wild-type (-70.0 ± 2.2 mV vs. -62.8 ± 1.2 mV, P = 0.0071), and the slope factor was also increased (7.96 ± 0.6 vs. 5.55 ± 0.4, P = 0.0015). These changes both reflect reduced channel availability at membrane potentials negative to the activation threshold (∼ -50 mV), consistent with increased inactivation from closed states. Voltage-dependent availability was then assessed in either 20 or 200 µM lidocaine using the same voltageclamp protocol (Figure 3b ). Both wild-type and R1623Q channels exhibited a dose-dependent hyperpolarizing shift in the voltage dependence of channel availability. Solid lines show least-squares fits of a Boltzmann function to the data (see legends for all fitted parameters). The effect of 200 µM lidocaine on the R1623Q slope factor was especially profound (9.31 ± 0.45), reflecting a substantial loss of availability at -100 mV, consistent with the enhanced tonic block sensitivity noted for the mutant channel in Figure 1c . Thus, lidocaine blockade augments the effect of the R1623Q mutation to reduce channel availability at membrane potentials below the opening threshold, suggesting that the altered closedstate inactivation gating and lidocaine sensitivity of the mutant may be functionally linked.
We postulated that an interaction between closedstate inactivation and lidocaine should alter the kinetics of recovery from depolarization-induced block (that is, use-dependent block). In Figure 4 , recovery of availability for wild-type and R1623Q was assessed at -80 mV, a membrane potential where R1623Q channels undergo more closed-state inactivation (Figure 3a) . In control and drug-exposed (20 µM) conditions, both wild-type and mutant channels exhibited biexponential recovery kinetics (solid lines, Figure 4 ) characterized by a prominent rapid component (τ ∼10-20 ms) and a small slow component (τ ∼ 80-150 ms; see Figure 4 legend for fitted parameters). Consistent with previous studies (15), 20 µM lidocaine did not delay the recovery of the wild-type channels following a 50-millisecond depolarizing pulse (Figure 4a ). In contrast, this low concentration of lidocaine significantly delayed recovery of R1623Q channels (Figure 4b ), increasing the amplitude of the slow component from 18 to 36%. In similar experiments that measured recovery at -100 mV, 20 µM lidocaine did not slow either wild-type or R1623Q recovery (data not shown), consistent with the minimal steady-state block of R1623Q at more hyperpolarized membrane potentials (see Figure 3b) .
Effects of lidocaine on unitary R1623Q currents. We used single-channel recording to distinguish between enhanced closed-state inactivation and open-state block as the basis of the augmented lidocaine sensitivity of R1623Q. Figure  5 shows unitary current records from HEK-293 cells stably expressing wild-type (left) and R1623Q channels (right) in the absence or presence of 200 µM lidocaine. Inspection of the current records reveals that the R1623Q mutation increased the number of openings during each depolarization and also lengthened the duration of the openings (22, 23) . The current records suggest lidocaine reduced the overall number of openings, but had little effect on the character of individual openings.
To analyze these effects quantitatively, we first examined the mean open time. Conversely, inspection of the R1623Q unitary current records suggests that lidocaine did suppress the number of late openings, an effect consistent with the druginduced acceleration of whole-cell current decay ( Figures  1 and 2 ). For R1623Q patches held at -100 mV before depolarization, 200 µM lidocaine decreased the number of openings per sweep (corrected for channel number) from 1.36 ± 0.09 (n = 6) to 0.61 ± 0.20 (n = 4, P = 0.004). We also assembled ensemble-average records from cells expressing either wild-type or R1623Q channels ( Figure  6a ) to determine the effect of lidocaine on the peak probability of channel opening (peak P open ). There were 2 notable differences between the wild-type and R1623Q data. First, from a holding potential of -120 mV, the drug-free peak probability of channel opening was far greater for R1623Q than wild-type (see also summary
Figure 4
Time-dependent recovery of availability at -80 mV. HEK cells expressing either WT (a)or mutant (b) Na channels were subjected to the voltageclamp protocol shown in the inset in the presence or absence of lidocaine. Data are plotted on a logarithmic scale to highlight the individual kinetic components of recovery. Fractional recovery was assessed as the ratio of peak I Na during the second, relative to first, pulse (P2/P1) and is normalized to the 1,000-millisecond data point to eliminate differences in tonic block at -80 mV (per Figure 3b) . The mean data were fitted to the biexponential function y = A 1 (1 -e -t/τ1 ) + A 2 (1 -e -t/τ2 ), where A 1 , τ 1 are the amplitude and time constant of the prominent, rapid recovery component, and A 2 , τ 2 reflect a smaller, slow-recovery component. Table 1 .
data from a number of patches, Figure 6b) . Figure 3a clarifies that both wild-type and R1623Q drug-free channels are fully available at -120 mV. Hence, this drug-free difference in the peak probability of channel opening does not arise from differences in closed-state inactivation, but may result from the longer open time for R1623Q, which increases the likelihood that first openings will occur "in register". Second, 200 µM lidocaine had little to no effect on the peak P open of wild-type channels, but markedly reduced the peak P open of the R1623Q mutant, consistent with the increased tonic-block sensitivity of whole-cell R1623Q current compared with wild-type in Figure 1 . A unifying mechanism that rationalizes the increased lidocaine effect on R1623Q peak I Na (peak-opening probability) and macroscopic current decay rate (probability of late openings) is considered next.
Discussion
A domain IV-S4 mutation modifies inactivation and augments lidocaine sensitivity. Single-channel analysis (Figure 5) of the R1623Q gating phenotype reveals impaired open-state inactivation consistent with the slowed rate of whole-cell I Na decay (Figures 1, 2, and 6) , consistent with previous reports (22, 23) . In addition, the voltage-dependent availability of I Na is shifted to more negative membrane potentials (Figure 3) , indicating that inactivation from closed states is increased.
A slowing of open-state inactivation with coexistent enhancement of closed-state inactivation for this hH1 mutant is consistent with gating phenotypes reported for mutations in the domain IV, S4 segment of the human skeletal muscle Na channel (hSkM1) linked to paramyotonia congenita (24, 33) .
When exposed to lidocaine, R1623Q peak I Na is blocked more potently than wild-type hH1 in both whole-cell ( Figure 1 ) and single-channel ensembleaverage recordings (Figure 6 ), a pharmacologic phenotype shared by the analogous domain IV, S4 paramyotonia mutant in hSkM1 (R1448C) (20) . In addition, we find that the rate of R1623Q I Na decay is speeded to a much greater extent than wild-type when measured in whole-cell recordings from oocytes or HEK cells (Figures 1 and 2) or from ensemble-averaged unitary currents ( Figure 6 ). This enhanced drug sensitivity could result if the mutation increased the affinity of the open state for lidocaine, or, alternatively, the open-state inactivation mechanism could be sensitive to lidocaine (22) . Figure 2b shows that the effect of lidocaine on the rate of R1623Q I Na decay was largely voltage independent from -30 to +20 mV, whereas the rate of cardiac Na channel open-state inactivation increases substantially over this membrane potential range (32, 34) . Moreover, Figure 5 indicates that a high lidocaine concentration (200 µM) that markedly speeded the rate of I Na decay and reduced the number of openings per sweep had no effect on the mean open time. Taken together, these findings suggest that the enhanced lidocaine sensitivity of R1623Q is not linked to an increase in open-state block nor to an enhanced rate of open-state inactivation.
Because lidocaine does not appear to influence inactivation from open states, we considered the possibility that increased closed-state inactivation may underlie the increased drug sensitivity of the mutant. In support of this notion, our results clarify that mutant channels held at membrane potentials near V rest are more susceptible to closed-state inactivation ( Figure  3a) , and R1623Q channels exposed to lidocaine at these membrane potentials are more susceptible to block than wild-type (Figure 3b ). During depolarization sufficient to open channels, a proportion of channels inac-
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The tivate directly from closed states without opening (35, 36) . If lidocaine block is somehow augmented by closed-state inactivation, then enhanced lidocaine block of the R1623Q mutant could develop rapidly during depolarization.
Could an interaction between lidocaine and closedstate inactivation upon depolarization explain the enhanced block of R1623Q peak current as well as the drug-induced speeding of I Na decay? Because closed, inactivated, and drug-bound states are all nonconducting, the interplay between closed-state inactivation and drug binding at membrane potentials sufficient to open the channel is difficult to assess directly. Hence, to examine the feasibility of this mechanism, we performed quantitative simulations using a simplified Na channel gating scheme (Figure 7a ) that recapitulates a general feature of contemporary cardiac Na channel gating models (37): channels could either open before inactivating or could inactivate directly from the closed state. The drug-free R1623Q phenotype was simulated by a reduction in the rate of open-state inactivation, as described previously (22) , plus an increase in the rate of closed-state inactivation (Figure 7 ). We first assessed whether drug binding to the inactivated state alone (regardless of the pathway to inactivation) could account simultaneously for lidocaine effects on peak I Na and I Na decay in R1623Q (Figure 7a (Figure 7b ). Given the assumption that the affinity of the inactivated channel for lidocaine exceeds that of the closed channel and assuming that closed drugbound channels do inactivate, microscopic reversibility constraints dictate that the likelihood of closed-state inactivation is increased by drug binding (see legend Figure 7 for explicit formulation). Under these conditions, the simulation indicates that 20 µM lidocaine was sufficient to markedly reduce the R1623Q I Na peak and also speed the rate of current decay (Figure 7b , model II middle, dotted line). The dashed line (Figure 7b , model II middle) shows the drug-modified current normalized to the control (drug free) current to emphasize the effect of lidocaine on the rate of current decay. In contrast, the same concentration of lidocaine minimally changed either characteristic of the wild-type current (model II, left), as seen experimentally (Figures 1 and 2) . We considered whether this mechanism could apply generally to autosomal dominant LQT3 SCN5A mutations. The gating consequences of these mutations dif- 
